title: Outcomes of stenting extra-small (≤2.25 mm) vessels using the Resolute zotarolimus-eluting stent (R-ZES).
abstract: OBJECTIVE
  We assessed long-term outcomes in patients with extra-small (XS) (≤2.25 mm) and small vessels (SV) (>2.25-2.75 mm) treated with the Resolute zotarolimus-eluting stent (R-ZES).
  
  
  RESULTS
  Data from eight studies including patients with XS or SV were pooled for this analysis. Among 2,141 patients (837 XS, 1,304 SV), three-year cumulative major adverse cardiac events (15.4% vs. 11.5%; adj. HR [95% CI]: 1.3 [1.0, 1.7], p=0.12), target lesion failure (12.4% vs. 9.3%, adj. HR: 1.1 [0.8, 1.5], p=0.56), and target lesion revascularisation (TLR: 6.9% vs. 4.5%, adj. HR 1.4 [0.9, 2.1], p=0.17) were greater in the XS cohort but were not significantly different after propensity adjustment. Target vessel revascularisation occurred more frequently in XS patients in both unadjusted and adjusted analyses (11.2% vs. 7.6%, adj. HR: 1.5 [1.1, 2.1], p=0.02). Stent thrombosis was low in both cohorts (1.2% vs. 0.6%, p=0.09). In the XS cohort, insulin-dependent diabetics had over twofold higher rates of TLR than non-diabetics (13.6% vs. 6.0%, p=0.02).
  
  
  CONCLUSIONS
  Long-term lesion-specific results among patients with XS vessels treated with the R-ZES were not significantly different from those among patients with SV, but specific patients with XS vessels (e.g., insulin-dependent diabetics) may remain at high risk for TLR.
authors.affiliation: Department of Medicine, Division of Cardiology, Columbia University Medical Center/New York Presbyterian Hospital, New York, NY, USA.
authors.forename: Manish A
authors.initials: MA
authors.lastname: Parikh
authors.forename: Jonathan
authors.initials: J
authors.lastname: Soverow
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Patrick
authors.initials: P
authors.lastname: Serruys
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Zuyi
authors.initials: Z
authors.lastname: Yuan
authors.forename: Robayaah
authors.initials: R
authors.lastname: Zambahari
authors.forename: Ajay
authors.initials: A
authors.lastname: Kirtane
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002317:Cardiovascular Agents / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000453:epidemiology / Q000628:therapy; D003328:Coronary Thrombosis / Q000453:epidemiology / Q000628:therapy; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000379:methods; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; C489443:zotarolimus; D020123:Sirolimus